Tag: Quality Systems

Addressing Poor Justification of Design Space During Scale-Up for Effective Tech Transfer In pharmaceutical manufacturing, effectively managing scale-up processes while justifying design space is crucial for ensuring successful tech transfers.…

Understanding the Impact of Excipient Variability During Scale-Up and Its Regulatory Implications In the pharmaceutical industry, the transition from laboratory-scale development to full-scale manufacturing can present various challenges, particularly concerning…

Assessing Process Knowledge Gaps During Comparability Evaluations to Mitigate GMP Risks In the evolving landscape of pharmaceutical development, ensuring that all critical process knowledge is captured during comparability assessments is…

Identifying Scale-up Risks During Pilot Scale: Investigative Action for GMP Compliance In pharmaceutical manufacturing, the transition from pilot to commercial scale can present significant challenges—particularly when risks encountered during piloting…

“`html Exploring Method Development Instability During Comparability Assessment: Addressing Downstream GMP Risks Method development instability during comparability assessments can pose significant risks to Good Manufacturing Practice (GMP) compliance in pharmaceutical…

Addressing the Gap in Process Knowledge During Transfer to Manufacturing: A CAPA Framework In pharmaceutical manufacturing and development, the transition of process knowledge from R&D to manufacturing is critical. When…

Understanding and Addressing Poor Justification of Design Space in Early Development The success of a pharmaceutical product often hinges on well-defined and justified design space during its early development stages.…

Identifying and Addressing Tech Transfer Readiness Gaps in Pharmaceutical Manufacturing The transfer of technology from research and development into manufacturing settings can be challenging, often revealing gaps that compromise the…

Method Development Instability During Comparability Assessment: A Structured Investigation Approach Pharmaceutical companies frequently face complex challenges during method development, particularly during comparability assessments. Method development instability can raise significant regulatory…

Underrating Formulation Robustness During Scale-up: Enhancing Data Package for Compliance In pharmaceutical manufacturing, the robust performance of formulations during scale-up is pivotal to maintaining product quality and regulatory compliance. When…

Addressing Method Development Instability During Comparability Assessment for Smooth Tech Transfer In the pharmaceutical industry, method development stability is vital during comparability assessments, particularly when shifting from small-scale development to…

Understanding Underestimated Formulation Robustness in Early Development and Data Package Improvement Strategies Underestimating formulation robustness during the early stages of pharmaceutical development can lead to significant regulatory challenges, delays in…